Analysts Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) PT at $49.00

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) have earned a consensus rating of “Moderate Buy” from the thirteen research firms that are covering the stock, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $49.00.

KYMR has been the subject of several analyst reports. Leerink Partners restated an “outperform” rating and issued a $60.00 target price on shares of Kymera Therapeutics in a report on Monday, September 9th. Oppenheimer upped their target price on Kymera Therapeutics from $52.00 to $56.00 and gave the company an “outperform” rating in a research note on Friday, September 27th. Wells Fargo & Company raised their price target on Kymera Therapeutics from $30.00 to $38.00 and gave the stock an “equal weight” rating in a research note on Monday, August 12th. Wolfe Research raised Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $65.00 price objective on the stock in a research report on Monday, August 26th. Finally, Leerink Partnrs upgraded Kymera Therapeutics to a “strong-buy” rating in a research report on Monday, September 9th.

Insider Buying and Selling

In other Kymera Therapeutics news, Director Pamela Esposito sold 13,500 shares of the firm’s stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total transaction of $651,780.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other Kymera Therapeutics news, Director Jeffrey W. Albers sold 5,000 shares of the company’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $49.10, for a total transaction of $245,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Pamela Esposito sold 13,500 shares of the stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total value of $651,780.00. The disclosure for this sale can be found here. 15.82% of the stock is owned by insiders.

Institutional Investors Weigh In On Kymera Therapeutics

Hedge funds have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. raised its holdings in Kymera Therapeutics by 7.8% in the first quarter. Ameritas Investment Partners Inc. now owns 4,070 shares of the company’s stock worth $164,000 after purchasing an additional 295 shares in the last quarter. Comerica Bank raised its stake in shares of Kymera Therapeutics by 13.7% during the 1st quarter. Comerica Bank now owns 3,324 shares of the company’s stock worth $134,000 after acquiring an additional 400 shares in the last quarter. Keudell Morrison Wealth Management lifted its position in Kymera Therapeutics by 7.2% during the second quarter. Keudell Morrison Wealth Management now owns 7,105 shares of the company’s stock valued at $212,000 after acquiring an additional 480 shares during the last quarter. Congress Asset Management Co. MA boosted its stake in Kymera Therapeutics by 1.2% in the first quarter. Congress Asset Management Co. MA now owns 45,836 shares of the company’s stock valued at $1,843,000 after acquiring an additional 533 shares in the last quarter. Finally, Principal Financial Group Inc. grew its holdings in Kymera Therapeutics by 4.7% in the first quarter. Principal Financial Group Inc. now owns 12,098 shares of the company’s stock worth $486,000 after purchasing an additional 547 shares during the last quarter.

Kymera Therapeutics Price Performance

Shares of NASDAQ KYMR opened at $46.56 on Tuesday. Kymera Therapeutics has a 1-year low of $9.60 and a 1-year high of $53.27. The business’s 50 day moving average is $46.54 and its two-hundred day moving average is $39.96. The stock has a market capitalization of $2.86 billion, a P/E ratio of -18.55 and a beta of 2.21.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.58) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.10. The company had revenue of $25.60 million for the quarter, compared to analyst estimates of $12.55 million. Kymera Therapeutics had a negative return on equity of 28.88% and a negative net margin of 178.27%. Kymera Therapeutics’s quarterly revenue was up 55.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.67) EPS. As a group, equities research analysts anticipate that Kymera Therapeutics will post -2.85 earnings per share for the current fiscal year.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.